We are building the iron products of the future

Chairman & CEO

Cato Crogh is Chairman and CEO of Bio Vitos Ltd and the driving entrepreneurial force behind the company’s development.

He has more than 30 years of experience as an entrepreneur and investor, with a background in building and developing companies across technology, digital platforms and capital markets.

Within Bio Vitos, Cato has played a central role in identifying the commercial opportunity surrounding iron succinate and in building the company around its intellectual property and clinical development programs.

He has personally been a key financier of Bio Vitos’ clinical development to date and has driven the company’s strategy, financing, international expansion and corporate development.

Contribution to Bio Vitos:

Cato provides the entrepreneurial and commercial leadership of the company, connecting Bio Vitos’ scientific assets with financing, strategic partnerships and international growth opportunities.

His primary responsibility is to transform Bio Vitos from a clinical development company into an internationally recognized life-science company with commercially valuable products and intellectual property.

Chief Medical Officer – CMO

Dr. Sven Rohmann brings more than 35 years of international experience from pharmaceuticals, biotechnology, clinical development and corporate leadership.

His career includes senior positions within major pharmaceutical companies including Novartis and Merck-Serono, as well as leadership roles in biotechnology companies.

He has extensive experience in clinical development, regulatory strategy, business development, licensing, partnerships, financing and M&A.

Within Bio Vitos, Sven serves as Chief Medical Officer and provides senior medical and pharmaceutical leadership for the company’s clinical and regulatory development.

Contribution to Bio Vitos:

Sven provides the bridge between Bio Vitos’ scientific research and the international pharmaceutical industry.

His responsibilities include medical strategy, clinical development, regulatory positioning, pharmaceutical partnerships and interaction with potential international industry partners.

His combination of medical, scientific, pharmaceutical and commercial experience is particularly important as Bio Vitos moves from clinical validation toward international commercialization.

Scientific & Clinical Research Lead – FEMININ & MAXFERMAN

Professor Fredrik Nyström is Professor of Internal Medicine at Linköping University and Senior Consultant in Internal Medicine with a special focus on endocrinology.

He has more than three decades of experience as a physician and researcher, with extensive research into metabolic health, cardiovascular risk factors, diabetes, obesity and related areas.

Professor Nyström leads the scientific work behind Bio Vitos’ FEMININ and MAXFERMAN clinical research programs.

FEMININ investigates iron-related outcomes in women, while MAXFERMAN expands Bio Vitos’ research program into men.

Contribution to Bio Vitos:

Fredrik provides the independent academic and scientific leadership required to design, execute, analyse and communicate high-quality clinical research.

His role is central to building the scientific evidence behind Bio Vitos’ products and future medical and commercial positioning.

Clinical Project Manager – FEMININ & MAXFERMAN

Viktor Nyström is responsible for the practical project management and coordination of Bio Vitos’ FEMININ and MAXFERMAN clinical programs.

His role is to ensure that the research programs move efficiently from planning through recruitment, data collection, coordination and completion.

Working closely with Professor Fredrik Nyström and the wider Bio Vitos team, Viktor provides the operational link between scientific planning and day-to-day execution.

Contribution to Bio Vitos:

Viktor brings operational structure and continuity to Bio Vitos’ clinical programs.

His responsibility is to ensure that the company’s research projects are translated from scientific protocols into efficiently executed clinical studies.

Chief Marketing Officer – Europe

Andreas Stigas leads Bio Vitos’ commercial and marketing development across Europe.

He brings experience from MedTech, digital health, healthcare and international business development, including work focused on bringing advanced healthcare solutions to patients and healthcare professionals.

His role at Bio Vitos is to develop the company’s European market strategy and establish relationships with potential commercial, healthcare and strategic partners.

Contribution to Bio Vitos:

Andreas is responsible for helping translate Bio Vitos’ clinical and scientific achievements into a clear European commercial proposition.

His focus includes European market development, strategic partnerships, positioning and preparing Bio Vitos for future commercialization across key European markets.

Digital Health & Technology

Takis Kaplanis contributes to Bio Vitos’ development within digital health and technology.

A key part of Bio Vitos’ future strategy is to combine pharmaceutical innovation with new digital technologies that can improve awareness, identification and management of iron deficiency.

This includes the development of digital concepts connected to Bio Vitos and the broader ecosystem surrounding the company’s products.

Contribution to Bio Vitos:

Takis provides technological and digital-health expertise and supports the development of scalable digital solutions that can complement Bio Vitos’ pharmaceutical and clinical programs.

His role helps Bio Vitos connect traditional life science with the rapidly developing field of digital health.

Business Development & Operations

Emil Åkesson supports Bio Vitos in business development and operational execution as the company moves from research and clinical development toward international commercialization.

His role is focused on supporting the practical implementation of Bio Vitos’ growth strategy and coordinating activities across the company’s expanding network.

Contribution to Bio Vitos:

Emil strengthens Bio Vitos’ ability to turn strategic decisions into practical execution and supports management as the organization, partnerships and international activities expand.

Chief Marketing Officer – Nordics

Håkan Waxegård is responsible for Bio Vitos’ marketing and brand development across the Nordic region.

He is an experienced entrepreneur, marketing strategist and communications professional with decades of experience in creating and developing brands, concepts and large-scale projects.

He is particularly known as one of the founders behind Hultsfredsfestivalen and as the founder of Lollipop Festival, and has extensive experience in PR, media, marketing, events and audience development.

During his career, he has built a substantial network across Scandinavian media, business, culture and communications.

Contribution to Bio Vitos:

Håkan brings extensive experience in creating public awareness and building strong brands.

Within Bio Vitos, his focus is on Nordic marketing, communications, media relationships, brand positioning and ultimately building awareness around Bio Vitos and its products as they approach the market.

Chief Marketing Officer – Asia

Jamshaid Iman is responsible for Bio Vitos’ market development and commercial relationships across Asia.

Asia represents an important long-term opportunity for Bio Vitos due to the size of the population, rapidly developing healthcare markets and the potential demand for effective and well-tolerated iron supplementation and treatment solutions.

Contribution to Bio Vitos:

Jamshaid’s role is to build Bio Vitos’ presence and network across selected Asian markets.

His responsibilities include identifying potential commercial partners, distributors, strategic relationships and market-entry opportunities.

He provides Bio Vitos with a dedicated regional resource for developing one of the world’s largest potential healthcare markets.

Strategic restructuring towards drug development and acquisition of rights around ferrous succinate.

Focus on EFSA approval and planned listing on the US stock exchange.